Results 11 to 20 of about 540,756 (159)
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network [PDF]
, 2013 Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.Berking, Carola, Armin Justich (103646), Simone M. Goldinger, Daniela Göppner, Lucie M Heinzerling, Stephan Grabbe (103633), Clemens L. Bockmeyer, Robert Caroline, Thomas Eigentler, Christine Mateus (103663), Moos, Roger von, Loquai Carmen, Gerold Schuler, Dirk Schadendorf (103684), Christina Klein, Pätzold, Sylvie, Hundorfean, Gheorghe, Beatrice Schuler-Thurner, Göppner Daniela, Ralf Gutzmer (103628), Patrik Weder, Robert, Caroline, Bockmeyer, Clemens L., Dirk Schadendorf, Kaehler, Katharina C., Thomas Eigentler (103619), Katharina C. Kaehler, Gheorghe Hundorfean, Christine Mateus, Simone M. Goldinger (103594), Claus Garbe, Satzger, Imke, Ralf Gutzmer, Sylvie Paetzold (103676), Peter Mohr, Uwe Trefzer, Voskens, Caroline J, Carmen Loquai (103597), Bockmeyer Clemens L., Vaubel, Julia, Jens Ulrich, Wilhelm, Tabea, Bockmeyer, Clemens Luitpold, Julia Vaubel, Hauschild Axel, Mohr, Peter, Gheorghe Hundorfean (103642), Caroline J. Voskens, Justich, Armin, Hauschild, Axel, Fluck Michael, Loquai, Carmen, Schadendorf, Dirk, Beatrice Schuler-Thurner (103693), Satzger Imke, Göppner, Daniela, Carola Berking, Weder Patrik, Hundorfean Gheorghe, Eigentler, Thomas Kurt, Grabbe, Stephan, Ulrich Jens, Armin Justich, Rüdiger Hein (71354), Garbe Claus, Ulrich, Jens, Eigentler Thomas, Schadendorf Dirk, Gutzmer Ralf, Mateus Christine, Imke Satzger, Weder, Patrik, Ullrich Keller (103650), Lucie M. Heinzerling (103723), Gerold Schuler (103690), Axel Hauschild (103637), Christina Klein (103657), Michael Fluck, Tanja Bergmann (103612), Axel Hauschild, Paetzold Sylvie, Katharina C Kaehler, Wilhelm Tabea, Keller, Ullrich, Schlaeppi Marc, Goldinger, Simone M., Claus Garbe (48881), Berking Carola, Heinzerling, Lucie, von Moos Roger, Simone M Goldinger, Trefzer Uwe, Uwe Trefzer (72075), Rüdiger Hein, Mateus, Christine, Caroline Robert, Tabea Wilhelm (103712), Schuler Gerold, Dummer, Reinhard, Schuler-Thurner Beatrice, Roger von Moos, Hein Rüdiger, Eigentler, Thomas, Paetzold, Sylvie, Caroline J Voskens, Caroline J. Voskens (103590), Schuler-Thurner, Beatrice, Roger von Moos (103705), Patrik Weder (103709), Lucie M. Heinzerling, Kaehler, Katharina C, Voskens, Caroline J., Fluck, Michael, Imke Satzger (103681), Schuler, Gerold, Tanja Bergmann, Marc Schlaeppi (103687), Bergmann, Tanja Regina, Julia Vaubel (103700), Bergmann Tanja, Heinzerling, Lucie M., Stephan Grabbe, Klein Christina, Caroline Robert (103600), Carola Berking (103608), Kähler, Katharina C., Peter Mohr (103669), Klein, Christina, Tabea Wilhelm, Reinhard Dummer (103718), Goldinger Simone M., Reinhard Dummer, Marc Schlaeppi, Gutzmer, Ralf, Hein, Rüdiger, Clemens L Bockmeyer, Sylvie Paetzold, Michael Fluck (103622), Kaehler Katharina C., Justich Armin, Voskens Caroline J., Carmen Loquai, Vaubel Julia, Grabbe Stephan, Keller Ullrich, Mohr Peter, Jens Ulrich (103696), Trefzer, Uwe, Katharina C. Kaehler (103604), Bergmann, Tanja, Heinzerling Lucie M., Dummer Reinhard, et al, Goldinger, Simone M, Daniela Göppner (103715), Garbe, Claus, Clemens L. Bockmeyer (103616), Schlaeppi, Marc, Ullrich Keller, von Moos, Roger, Voskens, Caroline J;Goldinger, Simone M;Loquai, Carmen;Robert, Caroline;Kaehler, Katharina C;Berking, Carola;Bergmann, Tanja;Bockmeyer, Clemens L;Eigentler, Thomas;Fluck, Michael;Garbe, Claus;Gutzmer, Ralf;Grabbe, Stephan;Hauschild, Axel;Hein, Rüdiger;Hundorfean, Gheorghe;Justich, Armin;Keller, Ullrich;Klein, Christina;Mateus, Christine;Mohr, Peter;Paetzold, Sylvie;Satzger, Imke;Schadendorf, Dirk;Schlaeppi, Marc;Schuler, Gerold;Schuler-Thurner, Beatrice;Trefzer, Uwe;Ulrich, Jens;Vaubel, Julia;von Moos, Roger;Weder, Patrik;Wilhelm, Tabea;Göppner, Daniela;Dummer, Reinhard;Heinzerling, Lucie M +160 morecore +2 more sourcesIPILIMUMAB IN THERAPY OF METASTATIC MELANOMA
Медицинский совет, 2016 Metastatic melanoma remains a refractory disease. Great progress in therapy of metastatic melanoma patients has been made in the recent five years. Targeted immunotherapy – a selective effect on lymphocytes signal molecules - became a principally new ...I. V. SAMOILENKO, G. Y. KHARKEVICH, L. V. DEMIDOV +2 moredoaj +1 more sourcePaired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome
Journal for ImmunoTherapy of Cancer, 2022 Background Immune checkpoint inhibitors (ICI) can lead to long-term responses in patients with metastatic melanoma. Still many patients with melanoma are intrinsically resistant or acquire secondary resistance.Kalijn Bol, Johannes Textor, Carl G Figdor, I Jolanda M de Vries, Lieke L van der Woude, Mark A J Gorris, Kiek Verrijp, Leonie I Kroeze, Avital L Amir, Jelena Meek +9 moredoaj +1 more sourceMetastatic Melanoma in Horses [PDF]
Journal of Veterinary Internal Medicine, 2002 Abstract The clinical and pathologic findings are reviewed for 14 horses with metastatic melanoma. All were older gray horses, with an average age of 16 years. The most common sites of primary tumors were the ventral tail, perineum, and parotid salivary gland.Katherine Cole, MacGillivray, Raymond W, Sweeney, Fabio, Del Piero +2 moreopenaire +2 more sourcesMETASTATIC MELANOMA WITHOUT CLINICALLY EVIDENT PRIMARY TUMOR
Сибирский онкологический журнал, 2017 The purpose of the study was to systematize the data available in the modern literature on the diagnosis and treatment of metastatic melanoma without clinically evident primary tumor. Materials and methods.V. Sh. Rzaeva, G. I. Gafton, V. V. Anisimov, Y. V. Semiletova, M. Yu. Myasnyankin, I. G. Gafton +5 moredoaj +1 more sourceLow-metastatic melanoma cells acquire enhanced metastatic capability via exosomal transfer of miR-199a-1-5p from highly metastatic melanoma cells
Cell Death Discovery, 2022 The mean survival of metastatic melanoma is less than 1 year. While the high mortality rate is associated with the efficient metastatic colonization of the involved organs, the underlying mechanisms remain elusive.Qiting Zhao, Hao Chen, Xiaoshuang Li, Bin Zeng, Zhiwei Sun, Doudou Liu, Yuting Chen, Yuhan Zhang, H. Rosie Xing, Jianyu Wang +9 moredoaj +1 more sourceA randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma : an update [PDF]
, 2008 At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of ...Middleton, M. (Mark), Corrie, P, Middleton, M, Dunn, J., East, C, Lorigan, P; id_orcid, Hern, A., Biswas, S., Wrigley, J., Lorigan, P., Wrigley, J, Dunn, Janet A., Marshall, A. (Andrea), Corrie, P., East, C., Marshall, A. +15 morecore +1 more sourceMetastatic melanoma of the gallbladder [PDF]
Cancer, 1979 Metastatic involvement of the gallbladder in melanoma is rare, but constitutes the most common metastatic lesion involving this organ. Two cases of metastatic melanoma to the gallbladder with radiographic evidence of gallbladder abnormality prior to surgery are presented.P M, McFadden, E T, Krementz, W M, McKinnon, L L, Pararo, R F, Ryan +4 moreopenaire +2 more sources